Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

896 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H; GESIDA HIV/HCV cohort. Berenguer J, et al. Among authors: ortega e. J Antimicrob Chemother. 2009 Jun;63(6):1256-63. doi: 10.1093/jac/dkp106. Epub 2009 Apr 10. J Antimicrob Chemother. 2009. PMID: 19363085 Clinical Trial.
Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program.
Pérez-Elias MJ, Sánchez-Conde M, Soriano V, Mallolas J, Luque I, Rodríguez-Alcántara F; Fosamprenavir Expanded Access Program Group. Pérez-Elias MJ, et al. Enferm Infecc Microbiol Clin. 2009 Jan;27(1):28-32. doi: 10.1016/j.eimc.2008.05.002. Epub 2009 Jan 9. Enferm Infecc Microbiol Clin. 2009. PMID: 19218000 Clinical Trial.
Saquinavir exposure in HIV-infected patients with chronic viral hepatitis.
Moltó J, Llibre JM, Ribera E, Mínguez C, del Río JS, Pedrol E, Vallecillo G, Cedeño S, Valle M, Miranda C, Negredo E, Clotet B; SQV-HEP Study Group. Moltó J, et al. J Antimicrob Chemother. 2009 May;63(5):992-7. doi: 10.1093/jac/dkp070. Epub 2009 Mar 11. J Antimicrob Chemother. 2009. PMID: 19279052
Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus.
Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J; GESIDA3603/5607 Study Group. Berenguer J, et al. Hepatology. 2009 Aug;50(2):407-13. doi: 10.1002/hep.23020. Hepatology. 2009. PMID: 19575364
The future of antiretroviral therapy: challenges and needs.
Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F; HIV 2020 Project. Moreno S, et al. J Antimicrob Chemother. 2010 May;65(5):827-35. doi: 10.1093/jac/dkq061. Epub 2010 Mar 12. J Antimicrob Chemother. 2010. PMID: 20228080 Review.
Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J, López-Aldeguer J, Alvarez-Pellicer J, De Miguel J, Crespo M, Guardiola JM, Tellez MJ, Galindo MJ, Arponen S, Barquilla E, Bellón JM, González-García J; GESIDA 36/03 and 50/06 Study Groups. Berenguer J, et al. J Antimicrob Chemother. 2011 Dec;66(12):2843-9. doi: 10.1093/jac/dkr362. Epub 2011 Sep 29. J Antimicrob Chemother. 2011. PMID: 21965432
Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.
Vigón L, Vázquez-Morón S, Berenguer J, González-García J, Jiménez-Sousa MÁ, Guardiola JM, Crespo M, de Los Santos I, Von Wichmann MA, Carrero A, Yélamos MB, Gómez J, Resino S, Martínez I; GESIDA 3603b Cohort Study Group. Vigón L, et al. Sci Rep. 2019 Aug 21;9(1):12163. doi: 10.1038/s41598-019-48592-5. Sci Rep. 2019. PMID: 31434968 Free PMC article.
896 results